| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| HUNT DOUGLAS M | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 2150, LOS ANGELES | /s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt | 10 Jul 2025 | 0001727172 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PBYI | Common Stock | Sale | $15,453 | -4,374 | -2.5% | $3.53 | 168,337 | 08 Jul 2025 | Direct | F1 |
| transaction | PBYI | Common Stock | Sale | $12,171 | -3,443 | -2% | $3.54 | 164,894 | 09 Jul 2025 | Direct | F1 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Adoption date of referenced 10b5-1(c) plan is: 12-14-2020 |
The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.